A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized

Sponsor
Centre Hospitalier Universitaire de Nice
Study ID
NCT06509984
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Epidermolysis Bullosa Simplex
  • Genodermatosis

Eligibility Criteria

Sex
ALL
Age
6 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The goal of this clinical trial is to Assessing the Efficacy and Safety of Apremilast in Patients \> 6 years of age with EB simplex generalized . The main question it aims to answer are: describe efficacity of this treatment. Participants will take treatments and have to use bullets during the study period.

Key Dates

First listed
Jul 19, 2024
Start date
Aug 6, 2024
Status verified
Feb 2025
Primary completion
Oct 1, 2025
Completion
Apr 1, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: apremilast treatment
    treatment by apremilast in two phases of challenge

Primary Outcome Measure

To describe efficacy of apremilast [ Time Frame: weeks 20 ]

Related Studies